Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: Analysis by chemotherapy cohort of the randomized phase III aurelia trial

Journal of Clinical Oncology

Volumn 33, Issue 32, 2015, Pages 3836-3838

  Poveda, Andres M ^a   Selle, Frédéric ^b   Hilpert, Felix ^c   Reuss, Alexander ^d   Savarese, Antonella ^e   Vergote, Ignace ^f   Witteveen, Petronella ^g   Bamias, Aristotelis ^h   Scotto, Nana ⁱ   Mitchell, Lada ⁱ   Pujade Lauraine, Eric ^j  

^a INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d AGO   (Germany)

^e REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^h UNIVERSITY OF ATHENS   (Greece)

ⁱ F HOFFMANN LA ROCHE LTD   (Switzerland)

^j UNIVERSITÉ PARIS DESCARTES   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DOXORUBICIN; PACLITAXEL; TOPOTECAN; ANTINEOPLASTIC AGENT; MACROGOL DERIVATIVE; PLATINUM DERIVATIVE;

ADULT; AGED; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CONTROLLED STUDY; FEMALE; HUMAN; INTENTION TO TREAT ANALYSIS; LETTER; MAJOR CLINICAL STUDY; OPEN STUDY; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PLATINUM RESISTANT RECURRENT OVARIAN CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; ANALOGS AND DERIVATIVES; CANCER GRADING; CANCER STAGING; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG RESISTANCE; KAPLAN MEIER METHOD; MIDDLE AGED; OVARIAN NEOPLASMS; PATHOLOGY; PROGNOSIS; RISK FACTOR; TREATMENT OUTCOME; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PLATINUM COMPOUNDS; POLYETHYLENE GLYCOLS; PROGNOSIS; RISK FACTORS; TOPOTECAN; TREATMENT OUTCOME;

EID: 85047290602     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.63.1408     Document Type: Letter

References (10)

1. Pujade-Lauraine E, Hilpert F, Weber B, et al: Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol 32:1302-1308, 2014
2. Stockler MR, Hilpert F, Friedlander M, et al: Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumabcontaining therapy for platinum-resistant ovarian cancer. J Clin Oncol 43:1309-1316, 2014
3. Sehouli J, Stengel D, Harter P, et al: Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer: A randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol 29:242-248, 2011
4. Lortholary A, Largillier R, Weber B, et al: Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: The CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO). Ann Oncol 23:346-352, 2012
5. Karlan BY, Oza AM, Richardson GE, et al: Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel n patients with recurrent ovarian cancer. J Clin Oncol 30:362-371, 2012
6. Monk BJ, Poveda A, Vergote I, et al: Anti-angiopoietin therapy with trebananibfor recurrent ovarian cancer (TRINOVA-1): A randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 15:799-808, 2014
7. Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676, 2007
8. Chan J, Brady M, Penson R, et al: Phase III trial of every-3-weeks paclitaxel vs. dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelia ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT01167712). Int J Gynecol Cancer 23:9, 2013(suppl 1; abstr 8)
9. Katsumata N, Yasuda M, Isonishi S, et al: Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritonea cancer (JGOG 3016): A randomised, controlled, open-label trial. Lancet Oncol 14:1020-1026, 2013
10. Pignata S, Scambia G, Katsaros D, et al: Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7) A randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 15:396-405, 2014